PABA (Para-Aminobenzoic Acid) and Peyronie's disease

What 2 graded rows on paba (para-aminobenzoic acid) agree on for Peyronie's disease, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the PABA (Para-Aminobenzoic Acid) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the PABA (Para-Aminobenzoic Acid) page, with its PubMed record.

Supplement

PABA (Para-Aminobenzoic Acid) Choose another

2 rows · 133 people

They agree: both rows found an improvement.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade C, is a randomized trial of 75 people (2005) and found an improvement.

The rows run from 58 to 75 people, published from 2005 to 2026: 2 single studies.

2 improved

Grade CPlaque size and curvature in early Peyronie's disease · Improved
RCT · n 75 · 2005 · Men with Peyronie's disease under 12 months, non-calcified plaque (103 randomized)
12 g/day (3 g four times a day) · 12 months
Responders 74.3% vs 50.0% on placebo; mean plaque size fell from 259 to 142 mm²; existing curvature did not improve but new or worsening curvature was less common. Pain relief did not differ.
Row on the PABA (Para-Aminobenzoic Acid) page · PubMed 15774254 (opens PubMed)
Grade DCurvature, plaque size and pain in Peyronie's disease vs colchicine · Improved
Observational · n 58 · 2026 · Men treated for Peyronie's disease at one clinic, 2012–2021 (30 on potassium PABA, 28 on colchicine)
Not stated in the abstract · 3 months, followed to 6 months
On potassium PABA, curvature improved by 33.5% and plaque size by 28.7%, with less pain; it outperformed colchicine for curvature at 3 and 6 months and for pain at 6 months, but plaque size did not differ between drugs.
Row on the PABA (Para-Aminobenzoic Acid) page · PubMed 42085088 (opens PubMed)